Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-blind Vehicle-controlled Parallel-dose Phase II Study Evaluating the Safety and Efficacy of a Recombinant Botulinum Neurotoxin Type A Injection (YY003) for the Treatment of Moderate to Severe Glabellar Lines in Adults

NCT06481475 is registered in ClinicalTrials.gov with Chongqing Claruvis Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06481475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06481475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-blind Vehicle-controlled Parallel-dose Phase II Study Evaluating the Safety and Efficacy of a Recombinant Botulinum Neurotoxin Type A Injection (YY003) for the Treatment of Moderate to Severe Glabellar Lines in Adults
Lead sponsor
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
January 9, 2025
Completion date
December 28, 2025
Enrollment
153 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe glabellar lines